Navigation Links
NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Date:2/1/2008

ANN ARBOR, Mich., Feb. 1 /PRNewswire/ -- NanoBio Corporation is presenting safety and efficacy results on new topical treatments for herpes labialis (cold sores) and onychomycosis (toe nail fungus) at the annual meeting of the American Academy of Dermatology (AAD), being held February 1-5, 2008, in San Antonio.

The data being presented indicate that the company's topical lotions, composed of nanometer-sized droplets, have potent antiviral and antifungal effects without safety concerns or systemic absorption. Interim findings in subjects with cold sores demonstrate faster healing without skin irritation or safety concerns. Initial results in subjects with toe nail fungus indicate an excellent safety profile with no systemic absorption coupled with an ability to kill the fungi that cause onychomycosis, a common condition affecting up to 36 million people.

"We are very encouraged by our preliminary results," said James R. Baker Jr., M.D., founder and chairman of NanoBio Corporation. "Our human and animal studies show that NanoBio's products are well tolerated and without safety issues, adverse events or skin irritation concerns. Pharmacokinetic studies show no systemic absorption, a factor that enhances the safety profile."

Final results from a prior phase 2A study in herpes labialis, as well as interim findings from an ongoing phase 2B study, indicate a significant improvement in time to healing for subjects treated with NanoBio's antiviral product, NB-001.

Results from a phase 1 study in onychomycosis, as well as preclinical data being presented at the meeting, indicate that NanoBio's antifungal product, NB-002, can be safely applied to the skin at doses more than 1,000 times higher than the minimum concentration required to kill fungi.

"NB-002 exerts its effect locally by penetrating the skin and diffusing laterally underneath the nail plate to reach the dermatophytes and kill both active hyphae and spores -- without irritating the epithelium or being systemically absorbed," Baker said. "The absence of systemic involvement could provide a significant advance for onychomycosis therapy in terms of safety." Current oral (systemic) drugs for onychomycosis pose risks of hepatic and cardiac toxicity, as well as the potential for drug interactions, Baker added.

In addition to its safety and tolerability, NB-002 activity was documented against numerous fungi involved in cutaneous infections, including Candida albicans, Microsporum canis, Epidermophyton floccosum, Trichophyton mentagrophytes and Trichophyton rubrum.

NanoBio is currently conducting a double-blind, placebo-controlled, phase 2 study to further investigate the efficacy and safety of NB-002 in 443 subjects with onychomycosis. All subjects have been enrolled, and the study is expected to be completed in February 2009.

The company's topical treatments are based on a novel anti-infective platform comprising an oil-in-water emulsion and a surfactant. The nanodroplets readily penetrate hair follicles and skin pores to reach the site of infection without disrupting skin or mucous membranes. Upon contact with the pathogen, the nanodroplets directly interact with the pathogen's outer membranes to lyse the virus, fungus or bacteria.

Poster Titles -- Link to posters at http://www.nanobio.com

-- Safety, Tolerance, Pharmacokinetics, and Efficacy of Topical

Nanoemulsion NB-001 for the Treatment of Herpes Labialis

-- Development of a Novel Antiviral Drug (NB-001) for Topical Application

in Humans

-- Safety, Tolerance, and Pharmacokinetics of Topical Nanoemulsion (NB-

002) for the Treatment of Onychomycosis

-- Development of a Novel Antifungal Drug (NB-002) for Topical Application

in Humans

About NanoBio

NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.


'/>"/>
SOURCE NanoBio Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
5. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
10. Immunosyn Corporation Releases SF-1019 Study Results
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- Lianluo Smart Limited (Nasdaq: LLIT ... markets and sells medical devices and wearable sleep ... and international markets, recently attended the 2016 Guangdong ... Forum, co-hosted by the Institute of Interventional Cardiology ... Provincial People,s Hospital and Cardiology Department of Guangdong ...
(Date:12/2/2016)... Dec. 1, 2016 The concept of rare diseases ... given to this sector has been taking shape in ... the political aspects and initiatives related to orphan medicinal products ... the level of member states individually. Many member states in ... the space of orphan medicinal products, the result of which ...
(Date:12/2/2016)... Dec. 2, 2016 Allergan plc (NYSE: ... information on its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a ... the Company will repurchase $10 billion of its ordinary shares. ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs ... patients must find the one that works for them. When an inventor from Suisun ... that worked and decided to share it with others. , He developed a prototype ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... ... 2016 , ... Mediaplanet is proud to announce the launch ... innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians ... years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional Conference will ... Spa in Honolulu, offering local frontline clinicians the opportunity to extend their certified ... demand for supplemental training related to pain management has surged dramatically in recent ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the 5,000 ... unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition to ... been available in several ShopRite and FoodTown stores in NJ and received rave comments ...
Breaking Medicine News(10 mins):